Therapeutic monoclonal mntibodies: where have we come and where are we going?
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: SCANNON, Patrick (XOMA Corporation, Chief Scientific Officer, Berkeley, california, United States of America)
Publication in 1975 by Köhler and Milstein of methods for making monoclonal antibodies (mAbs) has resulted in a new drug class and correspondingly, a new global industry. This class of targeted therapeutics has substantially grown both in product numbers and total drug market share.
The growth of this market was initially limited by two.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.